First-line ribociclib (RIB) + letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: The University of Texas MD Anderson Cancer Center, Sheba Medical Center, Masaryk Memorial Cancer Institute, Centre Hospitalier Universitaire de Besançon, Curtin University, Strasbourg Oncologie Libérale, European Society of Surgical Oncology, National Cancer Centre Singapore, Sarah Cannon, Virginia Cancer Specialists, The Netherlands Cancer Institute, Borstkanker Onderzoek Groep, Oslo University Hospital, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Tel Aviv University, Rabin Medical Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2807639280